Free Trial

Urogen Pharma (URGN) Competitors

Urogen Pharma logo
$18.95 +0.95 (+5.26%)
As of 03:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

URGN vs. RARE, AMRX, CPRX, GMTX, OGN, ARWR, APLS, XENE, IBRX, and NAMS

Should you be buying Urogen Pharma stock or one of its competitors? The main competitors of Urogen Pharma include Ultragenyx Pharmaceutical (RARE), Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), Gemini Therapeutics (GMTX), Organon & Co. (OGN), Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS), Xenon Pharmaceuticals (XENE), ImmunityBio (IBRX), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry.

Urogen Pharma vs. Its Competitors

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Urogen Pharma (NASDAQ:URGN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, Urogen Pharma had 3 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 10 mentions for Urogen Pharma and 7 mentions for Ultragenyx Pharmaceutical. Urogen Pharma's average media sentiment score of 0.64 beat Ultragenyx Pharmaceutical's score of -0.21 indicating that Urogen Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ultragenyx Pharmaceutical
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Urogen Pharma
1 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ultragenyx Pharmaceutical has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 5.5% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 5.1% of Urogen Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Ultragenyx Pharmaceutical presently has a consensus target price of $83.64, suggesting a potential upside of 204.37%. Urogen Pharma has a consensus target price of $32.86, suggesting a potential upside of 73.43%. Given Ultragenyx Pharmaceutical's higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Urogen Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ultragenyx Pharmaceutical
0 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.93
Urogen Pharma
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.00

Urogen Pharma has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Urogen Pharma is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ultragenyx Pharmaceutical$590.69M4.40-$569.18M-$5.88-4.67
Urogen Pharma$91.87M9.53-$126.87M-$3.18-5.96

Ultragenyx Pharmaceutical has a net margin of -93.04% compared to Urogen Pharma's net margin of -150.68%. Ultragenyx Pharmaceutical's return on equity of -186.49% beat Urogen Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Ultragenyx Pharmaceutical-93.04% -186.49% -36.81%
Urogen Pharma -150.68%-97,487.15%-49.57%

Summary

Ultragenyx Pharmaceutical beats Urogen Pharma on 9 of the 17 factors compared between the two stocks.

Get Urogen Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding URGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

URGN vs. The Competition

MetricUrogen PharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$876.20M$3.04B$5.72B$9.52B
Dividend YieldN/A2.40%4.60%3.99%
P/E Ratio-5.9621.1228.0720.02
Price / Sales9.53340.60462.58104.32
Price / CashN/A43.2336.5558.97
Price / Book-90.228.338.645.90
Net Income-$126.87M-$55.19M$3.24B$258.50M
7 Day Performance24.07%5.91%4.08%2.12%
1 Month Performance38.09%17.69%10.68%12.62%
1 Year Performance15.81%5.36%34.47%19.25%

Urogen Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
URGN
Urogen Pharma
4.5082 of 5 stars
$18.95
+5.3%
$32.86
+73.4%
+10.0%$876.20M$91.87M-5.96200
RARE
Ultragenyx Pharmaceutical
4.35 of 5 stars
$27.17
-0.1%
$83.64
+207.9%
-39.5%$2.57B$590.69M-4.631,294Upcoming Earnings
Gap Down
AMRX
Amneal Pharmaceuticals
3.1369 of 5 stars
$8.13
-1.7%
$11.60
+42.6%
+8.0%$2.55B$2.83B-203.258,100
CPRX
Catalyst Pharmaceuticals
4.9232 of 5 stars
$20.72
-1.1%
$32.83
+58.5%
+20.0%$2.53B$534.65M13.2080News Coverage
Positive News
Analyst Revision
GMTX
Gemini Therapeutics
N/A$57.74
+1.5%
N/A+32.1%$2.50BN/A-57.7430
OGN
Organon & Co.
4.7681 of 5 stars
$9.57
+0.1%
$18.00
+88.2%
-53.5%$2.49B$6.40B3.334,000
ARWR
Arrowhead Pharmaceuticals
3.782 of 5 stars
$17.89
+1.4%
$43.71
+144.4%
-43.8%$2.47B$3.55M-12.78400News Coverage
Positive News
APLS
Apellis Pharmaceuticals
4.2298 of 5 stars
$19.43
+0.4%
$39.84
+105.0%
-46.3%$2.46B$775.84M-10.92770Upcoming Earnings
XENE
Xenon Pharmaceuticals
3.7513 of 5 stars
$31.42
-0.2%
$54.82
+74.5%
-29.1%$2.42B$7.50M-9.77210Positive News
Options Volume
IBRX
ImmunityBio
2.1548 of 5 stars
$2.73
-0.5%
$12.25
+349.5%
-43.5%$2.41B$14.74M-4.70590News Coverage
Analyst Forecast
NAMS
NewAmsterdam Pharma
3.7852 of 5 stars
$21.03
+0.0%
$42.89
+104.0%
+23.8%$2.36B$45.56M-11.184

Related Companies and Tools


This page (NASDAQ:URGN) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners